Patent intelligence · US
US 12104188
Modified caspase-9 polypeptides and methods of use thereof
Modified caspase-9 polypeptides and methods of use thereof
Patent details — US 12104188
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 1, 2024
- Expiration
- Sep 26, 2044
- Applicant
- Allogene Therapeutics, Inc.
- Claims
- 35
- CPC classes
- A61K, A61K2239/23, A61K31/7088, A61K35/17
Quick answer
US 12104188 (Modified caspase-9 polypeptides and methods of use thereof) is held by Allogene Therapeutics, Inc.. Status: granted. Granted Oct 1, 2024. Expires Sep 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Allogene Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 35
- CPC classes
- A61K, A61K2239/23, A61K31/7088, A61K35/17, A61K38/4873, A61K38/52
More from Allogene Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12404315
Protease-activating CD45-gate CAR
granted -
US 12365873
Methods for transducing immune cells
granted -
US 12295362
Formulations and processes for CAR T cell drug products
granted -
US 12221462
Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells
granted -
US 12215347
Chimeric antigen receptors with enhanced signaling and activities and uses thereof
granted -
US 12163153
Methods of manufacturing allogeneic CAR T cells
granted -
US 12163169
Inducible chimeric cytokine receptors
granted
Frequently asked questions
What is US patent 12104188?
US 12104188 (Modified caspase-9 polypeptides and methods of use thereof) is held by Allogene Therapeutics, Inc.. Status: granted. Granted Oct 1, 2024. Expires Sep 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12104188?
Allogene Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 16 pharmaceutical patents for this assignee.
When does US 12104188 expire?
Our index shows an expiration date of Sep 26, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.